EQUITY RESEARCH MEMO
Jupiter BioMedical Research
Generated 5/10/2026
Executive Summary
Conviction (model self-assessment)45/100
Jupiter BioMedical Research is a pre-clinical biotechnology company focused on developing small-molecule therapeutics for oncology and infectious diseases. The company's lead candidates, JBR-102 and JBR-201, target glioblastoma multiforme (GBM) and antiviral applications against measles and herpes viruses, respectively. Founded in 2015 and headquartered in Florida, the company is capitalizing on unmet medical needs in aggressive brain cancer and emerging viral threats. While still in early development, Jupiter's pipeline addresses significant market opportunities with limited existing treatment options.
Upcoming Catalysts (preview)
- Q2 2026Presentation of preclinical efficacy data for JBR-102 in GBM models65% success
- Q4 2026IND-enabling studies completion for JBR-201 antiviral program55% success
- TBDStrategic partnership or licensing deal for GBM program30% success
Locked sections
- · Pipeline Analysis
- · Competitive Landscape
- · Catalyst Calendar (full 12-month)
- · Bull Case
- · Bear Case
- · Counterfactual Scenarios
- · Valuation Notes
- · SEC Filing Highlights
- · Insider Activity
- · Literature Watch
- · Patent Landscape
- · Mechanism Cluster Map
- · Audio Briefing (5 min)